SubsidieMeestersHomeoproteins as novel therapies for neurodegenerative diseases
BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.
Projectdetails
Introduction
With the ageing of the population, neurodegenerative diseases will be a huge societal, health, and economic problem. There are no effective solutions that can stop the progression of these devastating diseases.
Project Overview
At BrainEver, we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs).
Homeoproteins
Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration.
Mechanism of Action
When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases.
Objectives
In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1 to treat patients with:
- Amyotrophic Lateral Sclerosis (ALS)
- Parkinson's Disease (PD)
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.523.750 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-10-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- BRAINEVERpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing LossHB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models. | EIC Accelerator | € 2.325.312 | 2022 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Revolutionary therapeutic treatment for stopping progression of Parkinson's diseaseHerantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition. | EIC Accelerator | € 2.500.000 | 2023 | Details |
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
4D Brain-Targeting Nanomedicines for Treating NeurodegenerationThis project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Probing (Orphan) Nuclear Receptors in NeurodegenerationNeuRoPROBE aims to develop chemical probes and PROTACs for orphan nuclear receptors TLX and Nurr1 using AI to advance therapeutic strategies against neurodegenerative diseases. | ERC Starting... | € 1.498.813 | 2022 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSISREGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue. | ERC Proof of... | € 150.000 | 2022 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
Probing (Orphan) Nuclear Receptors in Neurodegeneration
NeuRoPROBE aims to develop chemical probes and PROTACs for orphan nuclear receptors TLX and Nurr1 using AI to advance therapeutic strategies against neurodegenerative diseases.
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSIS
REGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue.